- Investing.com
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution processes of inflammation and has applications in a number of therapeutic indications, including acute and chronic inflammation; Tumor necrosis factor (TNF) receptor type II (TNFR2) agonist asset is a bivalent antibody molecule used to selectively stimulate TNFR2 receptor activity, without modulation of the TNFR1 signaling; and NKTR-255, an IL-15 receptor agonist designed to boost the immune system’s natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.
Metrics to compare | NKTR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNKTRPeersSector | |
---|---|---|---|---|
P/E Ratio | −0.8x | 0.0x | −0.5x | |
PEG Ratio | −0.03 | 0.00 | 0.00 | |
Price/Book | 7.9x | 0.8x | 2.6x | |
Price / LTM Sales | 1.2x | 2.2x | 3.1x | |
Upside (Analyst Target) | - | 50.9% | 48.6% | |
Fair Value Upside | Unlock | 27.1% | 8.9% | Unlock |